We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 1.97% | 7.75 | 7.70 | 7.80 | 7.75 | 7.65 | 7.70 | 1,248,169 | 14:44:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -3.93M | -0.0079 | -9.81 | 38M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/4/2024 09:25 | AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEN | blackhorse23 | |
15/4/2024 11:49 | It is one of their top priorities for this year | inaminute | |
15/4/2024 09:37 | Great this for #POLB Very positive to see the approval of multiple CAR T cell therapies for earlier treatment of multiple myelomaAs an oral preventative therapy for CRS #POLB 001 has the potential to enable broader, safer delivery of cancer immunotherapies to cancer patientshttps://x.co | burtond1 | |
12/4/2024 13:45 | How do u come to that conclusion? No point in going to the Nasdaq unless you're very very well capitalised. I'd say a Phase 2 Clinical trial will be necessary expecially since cytokine storm can effect multiple organs | chica1 | |
12/4/2024 13:00 | This will be on Nasdaq by year end | inaminute | |
12/4/2024 10:26 | Has CF new venture been ipo’d | anderson3 | |
12/4/2024 09:29 | Thanks an interesting read, especially as many quite some way from commercialisation on entry. | peterrr3 | |
11/4/2024 09:15 | Was reading this last night Lots of deals in the Bio--Pharma sectors. There's a decent amount of reverse mergers onto the Nasdaq with private placements. Interesting! www.biospace.com/art | chica1 | |
10/4/2024 18:09 | I am optimistic for at least a pump as the grant strike price needs to hold a 70% increase for a couple of weeks or the team won't be happy. I also don't see why they need execs like a full time in house corporate lawyer no matter how good, especially when the IP work is outsourced anyway.I was hoping for the application for an orphan to show fast track and less onerous trial requirements from the Fda along with longer protection but I don't see anything new on Wipo which could flag this. | peterrr3 | |
10/4/2024 10:29 | Nope wasn't referring to CF. POLB001 came out of the Hvivo incubator so that was well before they were acquired. And the 2 heavy hitters at Amryt that got the original Lojuxta Aergerion deal done were Joe Wiley and Rory Nealon.Im sure the new Ex Amryt hires are all good people but the jury is still out on the strategy. Making a 360 degree turn from a candidate for severe flu into Oncology is a big move. Then again lots of drugs have been recalibrated to treat different conditions.2 off the top of my head Botox and Viagra. | chica1 | |
10/4/2024 10:05 | I assume you are referring to CF. Without him, you would have no Company. His ability to persuade top class people to to join and manage the company is exemplary. | klosters65 | |
10/4/2024 09:31 | Maybe need to spend some time to see if they can find the Finals. As soon as 'Mouth of Ireland' turns up you can expect chaos. | eeza | |
10/4/2024 08:31 | Cash on hand will be interesting here. There's alot more pigs at the trough to feed with the new hires. At this stage I would have thought the hiring of more scientists (who are generally cheap and frugal)would be more beneficial to Poolbeg than an expensive sales and marketing team. They'll definitely be needing big Pharma help by year end. | chica1 | |
10/4/2024 05:46 | A senior moment Hotteruk6? I know them only too well :-) | lfdkmp | |
09/4/2024 18:44 | oops wrong board | hotteruk6 | |
09/4/2024 18:44 | I was expecting more volatility in the share price today.....I think a genuine revaluation has taken place and is fully underwritten at current price. It's now about new premises impact, new contracts....and progress towards that magical 100 mill......could be very boring for a few weeks or longer. | hotteruk6 | |
08/4/2024 18:21 | Where are these full year results then? | 1gw | |
03/4/2024 15:32 | Some decent chunks going thru. I need more data before I add again. | chica1 | |
02/4/2024 19:40 | Nice to see the rise back above 10p this afternoon. Full year results are overdue by last year's precedent, so hopefully not far away now. | 1gw | |
28/3/2024 15:50 | "I feel this is company that has all the right ingredients to be extremely successful." - John Hughman "My instinct would be - there's going to be lots of really good newsflow. You wouldn't get a team that capable going into a smaller business like Poolbeg unless they saw huge opportunity." - Paul Hill | cf456 | |
27/3/2024 09:28 | 3080 Could well explain his cash raising from hvo. I expect he needs some cash to get his new venture off the ground and for buying more mining assets off the liquidator. | pierre oreilly | |
26/3/2024 17:01 | Cathal's new toy. | eeza | |
26/3/2024 07:06 | The notice of allowance from the US Patent Office for a #POLB 001 patent featured in @SmallCaps_UKThe claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indicationhttps://sm | burtond1 | |
22/3/2024 09:46 | Bit of interest this morning, up we go. | rafboy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions